Merck’s Covid-19 Drug Molnupiravir has “major safety concerns”

Recently approved oral antiviral drug for COVID-19, Merck’s Molnupiravir, has “major safety concerns,” said Balram Bhargava, director general of ICMR (Indian Council of Medical Research) on January 5, 2022. He added that Molnupiravir has safety concerns including teratogenicity, severe damage to the bones and muscles, and mutagenicity. Thus, it is not added in the national task-force treatment of coronavirus. With this, he confirmed that the drug has not been added by the World Health Organisation (WHO) and the UK also. 

Bhargava said that the...

Molnupiravir: A potential COVID-19 drug

Facts You Must Know

Salt composition: Molnupiravir

Dosage form: Capsules

Packaging: Strip

Administration route: Oral

Prescription required: Yes

Storage: Store at room temperature.

Shelf life: 18 months

Common brand names: Monuvir and Lagevrio

Indication:  Adult patients with COVID-19 who are at risk of developing severe symptoms

Recommended dose: 800mg dose every 12 hours for 5 days

Pediatric Patients: Not recommended for use in patients aged below 19 years

What is Molnupiravir?


molnupiravir | covid-19 | Pharmaceuticals | SKF Pharmaceuticals | Lagevrio